TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05481541

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: written education
Description: Other names:~Written/E-Mobile training The study was conducted as a three-group randomized controlled trial to examine the effect of written/mobile education on the quality of life and sleep of patients undergoing transurethral resection of the prostate. Written education was applied to the first group and mobile education was applied to the second group. Group 3 formed the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: written education
Description: Other names:~Written/E-Mobile training The study was conducted as a three-group randomized controlled trial to examine the effect of written/mobile education on the quality of life and sleep of patients undergoing transurethral resection of the prostate. Written education was applied to the first group and mobile education was applied to the second group. Group 3 formed the control group.
Study: NCT04836325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial static magnetic field stimulation (tSMS)
Description: The intervention group will receive a treatment of tSMS in the primary motor cortex.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial static magnetic field stimulation
Description: The placebo group will receive a dummy treatment
Study: NCT04650880

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets with the same external appearance
Study: NCT05731856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Wearable
Description: Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phones. Participants will use the Apollo for at least 30 minutes after waking up and at least 30 minutes before bed on the corresponding settings for those times of the day. They will be given the Apollo Device TVS (10-200 Hz) to borrow, which they will be instructed to wear daily. They will be asked to wear the device until all study data is collected.
Study: NCT05883384

Intervention type: OTHER
Intervention: stool analysis , CBC, specific IgE FOR Cow milk protein allergy
Description: apply CoMiSS and food challenge test on patient whom suspected to have cow milk protein allergy.
Study: NCT05202158

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Addition of gentamicin to irrigation fluid during RIRS
Description: During the RIRS, the access sheath is placed first for security. Then, the stone in the kidney is detected with flexible URS and fragmented with a holmium laser. In this group of patients, 80 mg of gentamicin will be added to 3 liters of irrigation fluid while the stone is being fragmented.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Only irrigation fluid during RIRS
Description: During the RIRS, the access sheath is placed first for security. Then, the stone in the kidney is detected with flexible URS and fragmented with a holmium laser. In this group of patients, only irrigation fluid will be used while the stone is fragmented.
Study: NCT05569460

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06326307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tell Show and Do Guidance
Description: In this technique, the dentist tells explains the procedure using the Tell show and do method.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tell Show and Do Guidance
Description: In this technique, the dentist tells explains the procedure using the Tell show and do method.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Puppet Guidance
Description: In this technique, the dentist using the puppet to explains the procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Puppet Guidance
Description: In this technique, the dentist using the puppet to explains the procedure.
Study: NCT05463094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Glucophage® XR
Description: Participants will receive single oral dose of Test GXR RM tablet under fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Glucophage® XR
Description: Participants will receive single oral dose of Test GXR RM tablet under fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Glucophage® XR
Description: Participants will receive single oral dose of Test GXR RM tablet under fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Glucophage® XR
Description: Participants will receive single oral dose of Test GXR RM tablet under fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Glucophage® XR
Description: Participants will receive single oral dose of Reference GXR RM tablet under fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Glucophage® XR
Description: Participants will receive single oral dose of Reference GXR RM tablet under fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Glucophage® XR
Description: Participants will receive single oral dose of Reference GXR RM tablet under fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Glucophage® XR
Description: Participants will receive single oral dose of Reference GXR RM tablet under fasted or fed conditions.
Study: NCT05084404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: 4 mg/day of WY-8678 (guanabenz acetate)
Description: Patients with nonalcoholic fatty liver disease are administered 4 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: 8 mg/day of WY-8678 (guanabenz acetate)
Description: Patients with nonalcoholic fatty liver disease are administered 8 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
Study: NCT04988594

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus 207, Bifidobacterium lactis B420/205
Description: Cultures containing 3.7 × 10 \^ 9 CFU/mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus bulgaricus and Streptococcus thermophillus
Description: Cultures containing 3.7 × 10 \^ 6 CFU/mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No culture
Description: No probiotic cultures
Study: NCT06017635

Intervention type: OTHER
Intervention: Exposure factors
Description: 1. General information Name, gender, age, weight (kg), major diseases~2. Clinical data:~Non-contrast CT scan results of cranial CT on the first day of admission, serum SUR1, trpm4 and MMP-9 expression on the 1st, 4th, 7th and 14th days of admission, S100-β and NSE values on the 1st, 4th, 7th, and 14th days of admission, disturbance coefficient on the 1st, 4th, 7th, and 14th days of admission, Glasgow coma score on the 1st, 4th, 7th, and 14th days of admission, GOS-E score and Merriam-Webster Intelligence Scale score at 3 months of discharge.

Intervention type: OTHER
Intervention: Exposure factors
Description: 1. General information Name, gender, age, weight (kg), major diseases~2. Clinical data:~Non-contrast CT scan results of cranial CT on the first day of admission, serum SUR1, trpm4 and MMP-9 expression on the 1st, 4th, 7th and 14th days of admission, S100-β and NSE values on the 1st, 4th, 7th, and 14th days of admission, disturbance coefficient on the 1st, 4th, 7th, and 14th days of admission, Glasgow coma score on the 1st, 4th, 7th, and 14th days of admission, GOS-E score and Merriam-Webster Intelligence Scale score at 3 months of discharge.
Study: NCT06509568

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy followed by immunotherapy
Description: Patients in the nCRIT group will receive neoadjuvant concurrent chemoradiotherapy: radiation therapy will be administered using IMRT or VMAT with involved-field irradiation at a dose of PTV 41.4 Gy/23 fractions/31 days. Chemotherapy will consist of weekly administration of paclitaxel (albumin-bound) 50 mg/m² and carboplatin (AUC 2) for five weeks, given on the days of radiotherapy. Patients who do not progress on CT and meet immunotherapy criteria will receive fixed-dose toripalimab (200 mg IV) on days 8 and 29 after chemoradiotherapy, followed by minimally invasive esophagectomy four weeks after completing immunotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemoimmunotherapy
Description: Patients in the nCIT group will receive two cycles of TC chemotherapy combined with immunotherapy, specifically paclitaxel (albumin-bound) 100 mg/m² on days 1, 8, 15 or 260mg/m² d1, carboplatin (AUC=5) on days 1, and toripalimab (200 mg) on days 1. Minimally invasive esophagectomy will be performed 4-6 weeks after completing chemotherapy, and adjuvant immunotherapy is recommended for one year after surgery.
Study: NCT05131113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Physical exercise
Study: NCT06124638

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Panbio™ COVID-19/Flu A&B Panel
Description: The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users.
Study: NCT01668264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiograph

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiograph

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Study: NCT05408884

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social Support
Description: Social support phone buddy program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Support
Description: Social support phone buddy program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic income
Description: $750 per month for 12 months
Study: NCT05672836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enavogliflozin
Description: 0.3 mg 1 tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard-of-Care
Description: Standard-of-Care medical therapy plus Enavogliflozin matching placebo
Study: NCT04455841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000928
Description: INCB000928 will be administered at protocol defined dose.
Study: NCT05001633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified media content paradigm
Description: media content

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: media content experience
Study: NCT04455841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000928
Description: INCB000928 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000928
Description: INCB000928 will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Ruxolitinib will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Ruxolitinib will be administered at protocol defined dose.
Study: NCT04364126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home blood pressure apparatus
Description: Target \<125/80 mmHg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic blood pressure
Description: Target \<130/80 mmHg
Study: NCT05960747

Intervention type: OTHER
Intervention: Simulation group
Description: Specific training for medical students by using an augmented virtual reality simulator for thoracentesis
Study: NCT05885971

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Administration of the SCOFF-F and EDE-Q questionnaires
Description: The participants will answer to the SCOFF-F and EDE-Q questionnaires as well as socio-demographic questions

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Administration of the SCOFF-F and EDE-Q questionnaires
Description: The participants will answer to the SCOFF-F and EDE-Q questionnaires as well as socio-demographic questions
Study: NCT05265728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Administered as specified in the treatment arm
Study: NCT05502536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation programs with Individualized fairytales class
Description: In addition to traditional rehabilitation programs, 30 minutes per week for 12 sessions of individualized fairytales classes by a child and educational teacher for three months, to preschool children with Attention Deficit Hyperactivity Disorder and developmental delays in regular traditional rehabilitation programs
Study: NCT05236387

Intervention type: DRUG
Intervention: 99m Tc-TM
Description: Each patient will receive a single injection (0.1 ml) of 99mTc-TM (50 mcg) at the upper outer skin of the breast using an intradermal technique confirmed by the presence of a skin wheal.
Study: NCT06027528

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dentin graft mixed with autologous fibrin glue
Description: extracted tooth will be grinded into small particles to form dentin graft that will be mixed with autologous fibrin glue to be grafted in the extracted socket using centrifuge

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dentin graft
Description: extracted tooth will be grafted in the socket
Study: NCT05661097

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture mode
Description: Patients in the small hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture by hernia hook needle.Patients in the large hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture with hernia hook needle, continuous suture with barbed wire+hernia Intermittent full layer crochet suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture mode
Description: Patients in the small hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture by hernia hook needle.Patients in the large hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture with hernia hook needle, continuous suture with barbed wire+hernia Intermittent full layer crochet suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture mode
Description: Patients in the small hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture by hernia hook needle.Patients in the large hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture with hernia hook needle, continuous suture with barbed wire+hernia Intermittent full layer crochet suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture mode
Description: Patients in the small hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture by hernia hook needle.Patients in the large hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture with hernia hook needle, continuous suture with barbed wire+hernia Intermittent full layer crochet suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture mode
Description: Patients in the small hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture by hernia hook needle.Patients in the large hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture with hernia hook needle, continuous suture with barbed wire+hernia Intermittent full layer crochet suture.
Study: NCT05831189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBX2660
Description: RBX2660 should be administered to the right side of the colon (i.e., between the ileocecal valve and the hepatic flexure of the colon).
Study: NCT05719142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Picture exposure
Description: Participants are shown pictures for 15 minutes; 50 images in total, each shown for 6 seconds, and 3 times in total.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Picture exposure
Description: Participants are shown pictures for 15 minutes; 50 images in total, each shown for 6 seconds, and 3 times in total.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Picture exposure
Description: Participants are shown pictures for 15 minutes; 50 images in total, each shown for 6 seconds, and 3 times in total.
Study: NCT05175118

Intervention type: DEVICE
Group type: OTHER
Intervention: Minimal invasive surgical fixation of distal radius Fractures
Description: Fixation of distal radius Fractures by minimal invasive technique
Study: NCT06630325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study: NCT06433362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMOEP
Description: Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 3 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1,every 3 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 3 mg/m2, the maximum dose of 4mg),every 3 weeks; Drug: Etoposide Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3,every 3 weeks;
Study: NCT05632991

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided external oblique intercostal plane block
Description: ultrasound guided external oblique intercostal plane block 20 ml local anesthetic each side

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal Transversus Abdominis Plan Block Group
Description: ultrasound guided Subcostal Transversus Abdominis Plan Block Group 20 ml local anesthetic each side
Study: NCT06315166

Intervention type: DEVICE
Group type: OTHER
Intervention: triLift/Legend Pro+ Fractional RF System
Description: The triLift/Legend Pro+ Fractional investigational device is intended for the treatment of acne vulgaris when using Fractional RF energy.
Study: NCT06096675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: • Cardiac Rehabilitation
Description: Intervention group will have baseline 6-minute walk test and cardiopulmonary exercise test (CPET) testing followed by supervised cardiac rehabilitation program including planned 3 one hour sessions a week for a total of 12 weeks (planned 36 sessions). A post intervention 6-minute walk test and CPET test will be performed within 2 weeks of completion of the 12 week program.
Study: NCT06630325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT04864860

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: brown seaweed (ecklonia cava)
Description: The intervention product used in this study is a dietary supplement called Seanol that contain 13% pholoratannic polyphenol per capsule as stated by the manufacture company (Seanol inside, 4215 95th St SW Lakewood, WA 98499 USA). Other ingredients are dextrin, magnesium stearate and silica (in neglected percentage). The intervention supplement is encapsulated in vegetable cellulose that contains 500 Ecklonia cava extract (Seanol). The placebo will be dextrin (BETA CYCLODEXTRIN, NF) ordered from a pharmaceutical company MEDISCA (https://www.medisca.co.uk/). Dextrin was selected to account for the similar complex carbohydrate content of the intervention supplement. Placebo will be encapsulated in vegetable cellulose capsules that is identical in size and coulure to the intervention capsules. The empty capsules will be ordered from MEDISCA and will be encapsulated in by SPIMACO ADDWAIEH (SFDA registered pharmaceutical company) (http://www.spimaco.com.sa/).
Study: NCT06630325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT06214390

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single strategy
Description: In the single strategy, RRT weaning will be achieved when urine output exceeds 500ml/24h without diuretics or 2000ml/24h with diuretics use

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined strategy
Description: In the combined strategy, when urine output exceeds 500ml/day with or without diuretic use, RRT will be stopped during 48h to assess urinary indices (urinary creatinine and urea). Soon as urinary indices are higher than thresholds values (urinary creatinine \> 5.2mmol/day \[5\] and 3) urinary urea \> 1.35mmol/kg/day (using the patient's body weight at ICU admission) \[6\], RRT will be weaned. If they are lower, a RRT session will be perform after which the weaning process will be resume.
Study: NCT06630325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy